Press Releases Keyword Search Year None202220212020201920182017 Date Title 05/18/22 Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference 05/12/22 UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update 05/12/22 Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update 05/09/22 Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders 05/04/22 Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services 04/28/22 Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022 04/18/22 Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit 04/08/22 Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR) 03/31/22 Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes 03/17/22 Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update 03/01/22 Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference 02/23/22 Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa 01/04/22 Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
Press Releases Keyword Search Year None202220212020201920182017 Date Title 05/18/22 Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference 05/12/22 UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update 05/12/22 Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update 05/09/22 Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders 05/04/22 Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services 04/28/22 Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022 04/18/22 Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit 04/08/22 Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR) 03/31/22 Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes 03/17/22 Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update 03/01/22 Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference 02/23/22 Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa 01/04/22 Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
05/12/22 UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
05/12/22 Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
05/04/22 Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
04/08/22 Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)
03/31/22 Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes
03/17/22 Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
03/01/22 Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
02/23/22 Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
